{"id":"W2528329272","doi":"10.1056/nejmoa1607751","title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1434,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Otsuka Pharmaceutical; Celgene; Bristol-Myers Squibb; Incyte; Chugai Pharmaceutical; Spectrum Pharmaceuticals; Amgen","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04367413013929703,"score_gpt":0.3284536669106923,"score_spread":0.2847795367713952,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}